Articles
Growing Prevalence of Lung Cancer Accelerates Global Non-small Cell Lung Cancer Market
by Ranu Kurmi tmrA
research study, recently published by Transparency Market Research (TMR),
estimates the global non-small cell lung cancer (NSCLC) therapeutics market to
expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach
a value of US$15.1 bn by the end of the forecast period.The report, titled “Non
Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis,
Size, Share, Growth, Trends, and Forecast 2015 - 2023,” states that the
worldwide NSCLC market attained US$4.9 bn in 2014.
Non-small
cell lung cancer (NSCLC) has been identified as the most common type of
epithelial lung cancer. Adenocarcinomas, squamous cell carcinomas, and large
cell carcinomas are the major types of NSCLC. Unlike small cell lung cancer
(SCLC), NSCLC exhibits low receptivity to chemotherapy, owing to which, the
need for NSCLC therapeutics has been persistently escalating in the global
arena.
In this
research report, the global market for NSCLC therapeutics has been evaluated on
the basis of the drug class, the pipeline stage, and the regional spread of
this market. Based on the drug class, the market has been classified into
angiogenesis inhibitor, kinase inhibitor, epidermal growth factor receptor
blocker, microtubule stabilizer, PD-1/PD-L1 Inhibitor, and folate
antimetabolites.
In
2014, angiogenesis inhibitor was the most demanded drug class in the global
arena. The high efficiency of this drug class fueled its demand in the U.S.,
Japan, Europe, and other major regions.
Avastin
and Cyramza are the two main angiogenesis inhibitors available in this market.
Analysts expect this segment to expand at a CAGR of 1.80% during the forecast
period and increase from a value of US$1.6 bn in 2014 to US$2 bn by the end of
the forecast period.
Based
on the pipeline stage, NSCLC therapeutics has been categorized into early-stage
(phase 1 and phase 2) pipeline drugs and late-stage (phase 3) pipeline drugs. MEDI4736
(AstraZeneca), Avelumab (Pfizer Inc.), Abemaciclib (Eli Lilly and Co.), and
MPDL3280A (Roche) are the major late-stage pipeline drugs.
Regionally,
the study segments the global market for NSCLC therapeutics into Asia Pacific,
Europe, North America, and the Rest of the World. North America led the overall
market in 2014 and was closely followed by Asia Pacific. However, Asia Pacific
is anticipated to register the fastest growth rate over the forecast period.
Request A Sample
Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504
The presence of state-of-art
healthcare infrastructure and existence of a favorable reimbursement scenario
are the key factors that drove the North America NSCLC therapeutics market.
Besides, the growing awareness about NSCLC and the increasing implementation of
government initiative to curb lung cancer are likely to boost the Asia Pacific
market for NSCLC therapeutics in the coming years, notes the study.
AstraZeneca Plc, GlaxoSmithKline
Plc, Genentech Inc., Eli Lilly & Co., Boehringer Ingelheim, Pfizer Inc.,
Celgene Corp., Roche Holding AG, Sun Pharmaceutical Industries Ltd., and
Bristol-Myers Squibb are some of the leading players in the global NSCLC
therapeutics market, states the research report.
The global NSCLC market is
segmented into:
By
Drug Class
·
Angiogenesis
Inhibitor
o Avastin (bevacizumab)
o Cyramza (Ramucirumab)
·
Epidermal
Growth Factor Receptor Blocker
o Tarceva (erlotinib)
o Gilotrif (afatinib)
o Iressa (gefitinib)
·
Kinase
Inhibitor
o Xalkori (crizotinib)
o Zykadia (ceritinib)
·
Microtubule
Stabilizer
o Abraxane (paclitaxel
protein bound)
o Docetaxel
·
Folate
Antimetabolites
o Alimta (pemetrexed)
·
PD-1/
PD-L1 Inhibitor
o Opdivo (nivolumab)
o Keytruda (pembrolizumab)
By
Pipeline
·
Early-Stage
(Phase I and II)
·
Late-Stage
(Phase III)
o Avelumab Pfizer Inc.)
o MPDL3280A (Roche)
o MEDI4736 (AstraZeneca)
o Abemaciclib (Eli Lilly and
Co.)
o Others
By
Region
·
North
America
o U.S.
o Canada
·
Europe
o U.K.
o Germany
o Rest of Europe
·
Asia
Pacific
o Japan
o China
o Rest of Asia Pacific
·
Rest
of the World
About Us
Transparency
Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of
quantitative forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of analysts,
researchers, and consultants use proprietary data sources and various tools and
techniques to gather and analyze information.
TMR’s data
repository is continuously updated and revised by a team of research experts so
that it always reflects the latest trends and information. With extensive
research and analysis capabilities, Transparency Market Research employs
rigorous primary and secondary research techniques to develop distinctive data
sets and research material for business reports.
Contact
us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Sponsor Ads
About Ranu Kurmi 
tmr
0 connections, 0 recommendations, 50 honor points.Joined APSense since, January 12th, 2016, From pune, India.
Created on Dec 31st 1969 18:00. Viewed 0 times.
